Bridging the gap between preclinical and clinical microbicide trials: Blind evaluation of candidate gels in murine models of efficacy and safety

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Segarra, Theodore J ^a   Fakioglu, Esra ^a   Cheshenko, Natalia ^a   Wilson, Sarah S ^a,c   Mesquita, Pedro M M ^a   Doncel, Gustavo F ^b   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULOSE SULFATE; PLACEBO; PRO 2000; AGENTS USED INTRAVAGINALLY; ANTIINFECTIVE AGENT; CELLULOSE; DRUG DERIVATIVE; NAPHTHALENESULFONIC ACID DERIVATIVE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GEL; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; INFECTION PREVENTION; INFECTION SENSITIVITY; LOW DRUG DOSE; MOUSE; NONHUMAN; VIRUS ISOLATION; ANIMAL; DRUG EFFECT; INTRAVAGINAL DRUG ADMINISTRATION; PATHOGENICITY;

HERPES; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS; SIMPLEXVIRUS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS; CELLULOSE; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; MICE; NAPHTHALENESULFONATES; POLYMERS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 80855144836     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027675     Document Type: Article

References (40)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
2. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359: 463-472.
3. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, et al. (2008) SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 3: e1474.
4. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360: 971-977.
5. Herold BC, Mesquita PM, Madan RP, Keller MJ, (2011) Female Genital Tract Secretions and Semen Impact the Development of Microbicides for the Prevention of HIV and Other Sexually Transmitted Infections. Am J Reprod Immunol 65: 325-333.
6. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, et al. (2009) Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 83: 10358-10365.
7. Weber J, Nunn A, O'Connor T, Jeffries D, Kitchen V, et al. (2001) 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 15: 1563-1568.
8. Saifuddin M DG, Tsai L, Gettie A, Bhom R, Cheng-Mayer C, (2008) Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. Microbicides 2008 New Delhi, India.
9. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977-1987.
10. Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, et al. (2008) Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS ONE 3: e3162.
11. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, et al. (2009) Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200: 599-608.
12. Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, et al. (2007) A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 195: 1332-1339.
13. Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, et al. (2009) Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther 14: 1113-1124.
14. Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, et al. (2007) Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 196: 1394-1402.
15. Anderson RA, Feathergill K, Diao XH, Chany 2nd C, Rencher WF, et al. (2004) Contraception by Ushercell (cellulose sulfate) in formulation: duration of effect and dose effectiveness. Contraception 70: 415-422.
16. Mashukova A, Wald FA, Salas PJ, (2011) Tumor necrosis factor alpha and inflammation disrupt the polarity complex in intestinal epithelial cells by a posttranslational mechanism. Mol Cell Biol 31: 756-765.
17. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, et al. (2005) Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 166: 409-419.
18. Al-Sadi R, Ye D, Dokladny K, Ma TY, (2008) Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 180: 5653-5661.
19. Mayer KH, Venkatesh KK, (2011) Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol 65: 308-316.
20. Critchlow CW, Wolner-Hanssen P, Eschenbach DA, Kiviat NB, Koutsky LA, et al. (1995) Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. Am J Obstet Gynecol 173: 534-543.
21. Patton DL, Cosgrove Sweeney YT, Paul KJ, (2008) A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 35: 889-897.
22. Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, et al. (2006) Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 74: 133-140.
23. Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, et al. (2000) Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. Aids 14: 85-88.
24. Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, et al. (2004) A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception 70: 233-240.
25. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, et al. (2007) SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2: e1312.
26. Vincent KL, Bell BA, Rosenthal SL, Stanberry LR, Bourne N, et al. (2008) Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: potential for assessment of microbicide safety. Sex Transm Dis 35: 269-275.
27. Vincent KL, Bourne N, Bell BA, Vargas G, Tan A, et al. (2009) High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis 36: 312-318.
28. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, et al. (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet.
29. Linehan MM, Richman S, Krummenacher C, Eisenberg RJ, Cohen GH, et al. (2004) In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J Virol 78: 2530-2536.
30. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, et al. (2010) Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 24: 1778-1781.
31. Fichorova RN YH, Delaney ML, Onderdonk AB, Doncel GF, (2011) A novel vaginal microflora colonization model provides new insight into microbicide mechanism of action. mBio in press.
32. Radhakrishnan Y, Fares MA, French FS, Hall SH, (2007) Comparative genomic analysis of a mammalian beta-defensin gene cluster. Physiol Genomics 30: 213-222.
33. Radhakrishnan Y, Hamil KG, Yenugu S, Young SL, French FS, et al. (2005) Identification, characterization, and evolution of a primate beta-defensin gene cluster. Genes Immun 6: 203-210.
34. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, et al. (2006) Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 177: 8658-8666.
35. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, et al. (2009) Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. Aids 23: 309-317.
36. Berges BK, Rowan MR, (2011) The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 8: 65.
37. Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, et al. (2010) Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One 5: e8781.
38. Ejercito PM, Kieff ED, Roizman B, (1968) Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol 2: 357-364.
39. Hendrickson BA, Guo J, Brown I, Dennis K, Marcellino D, et al. (2000) Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. Virology 271: 155-162.
40. Herold BC, Siston A, Bremer J, Kirkpatrick R, Wilbanks G, et al. (1997) Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens. Antimicrob Agents Chemother 41: 2776-2780.